KH Global Hanbang Raises Seed Funding for Wellness Supplements

KH Global Hanbang, a nascent player in the global wellness arena, has successfully closed its initial funding round, securing approximately $362,000. The seed investment was led by Korea Investment Accelerator, signaling strong backing for the company's mission to commercialize clinically validated traditional Korean medicine-based supplements.

The venture is uniquely positioned, having been established in March 2025 by three seasoned clinicians from the esteemed Kyung Hee University Korean Medicine Hospital. These founders bring over five decades of combined clinical practice and a deep understanding of traditional remedies, which they are integrating with modern scientific validation. This fusion of ancient wisdom and contemporary research forms the bedrock of their product development strategy, aiming to differentiate themselves in the increasingly competitive functional health market.

The global demand for preventive health solutions and natural wellness products is experiencing significant growth, fueled by aging demographics and a heightened consumer interest in holistic health approaches. KH Global Hanbang aims to capitalize on this trend by leveraging its direct ties to a major medical institution. The company asserts that its foundation in extensive prescription data and hospital-grade clinical evidence will foster greater trust among international consumers and distribution partners, a crucial factor in the premium wellness sector which is projected to reach hundreds of billions globally in the coming years.

KH Global Hanbang's initial product focus is a throat health supplement, derived from a well-documented herbal formula with a substantial prescription history exceeding 30 million instances at Kyung Hee University Korean Medicine Hospital. Beyond this flagship offering, the company has an ambitious pipeline featuring over 60 potential compounds targeting diverse health concerns, including cognitive function, metabolic health for aging adults, and hair loss solutions. This robust product development strategy underscores their commitment to addressing a broad spectrum of wellness needs.

To support its market entry, KH Global Hanbang has established a strategic manufacturing partnership. An MOU was signed in February with Biostream, a facility holding GMP certification, paving the way for contract manufacturing and dedicated equipment investment for their troche-form products. The company's go-to-market plan involves a phased approach, starting with general food and pre-approved functional health categories before progressing to more specialized products and international expansion.

Woohyun Nam, team lead at Korea Investment Accelerator, commented on the investment, highlighting the distinct capabilities of traditional Korean medicine in preventive care and expressing confidence in KH Global Hanbang's ability to innovate within the K-wellness space by drawing upon the heritage of Kyung Hee University Korean Medicine Hospital. Heejae Jeong, CEO of KH Global Hanbang, emphasized that decades of clinical prescription data serve as the genesis for their product innovation, aiming to translate scientifically validated traditional formulas into accessible daily health management tools for a global audience.